At the time of writing, Ionis Pharmaceuticals Inc [IONS] stock is trading at $32.69, up 2.77%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IONS shares have gain 6.00% over the last week, with a monthly amount glided 0.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on August 02, 2024, when BMO Capital Markets downgraded its rating to a Market Perform and also revised its price target to $60 from $67. Previously, Leerink Partners upgraded its rating to Outperform on July 24, 2024, and elevated its price target to $62. Bernstein upgraded its rating to a Mkt Perform but stick to its price target of $44 on June 14, 2024. Wolfe Research upgraded its rating to a Outperform but $58 remained the price target by the analyst firm on April 10, 2024. BofA Securities upgraded its rating to Buy for this stock on January 02, 2024, and upped its price target to $62. In a note dated October 23, 2023, BofA Securities upgraded an Neutral rating on this stock and boosted its target price from $33 to $52.
For the past year, the stock price of Ionis Pharmaceuticals Inc fluctuated between $30.23 and $52.34. Currently, Wall Street analysts expect the stock to reach $65 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $32.69 at the most recent close of the market. An investor can expect a potential return of 98.84% based on the average IONS price forecast.
Analyzing the IONS fundamentals
According to Ionis Pharmaceuticals Inc [NASDAQ:IONS], the company’s sales were 705.56M for trailing twelve months, which represents an -30.15% plunge. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.67%, Pretax Profit Margin comes in at -0.65%, and Net Profit Margin reading is -0.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -1.0 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.35 points at the first support level, and at 30.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 33.55, and for the 2nd resistance point, it is at 34.41.
Ratios To Look Out For
It is important to note that Ionis Pharmaceuticals Inc [NASDAQ:IONS] has a current ratio of 8.51. In addition, the Quick Ratio stands at 8.82 and the Cash Ratio stands at 0.78. Considering the valuation of this stock, the price to sales ratio is 7.32, the price to book ratio is 7.79.
Transactions by insiders
Recent insider trading involved O’NEIL PATRICK R., EVP CLO & General Counsel, that happened on Feb 04 ’25 when 6165.0 shares were sold. Chief Executive Officer, Monia Brett P completed a deal on Feb 04 ’25 to sell 38843.0 shares. Meanwhile, Officer Monia Brett P bought 40003.0 shares on Feb 04 ’25.
